Physician profile
Diana E Richards
NPI 1457412819
$4,303.44
in general payments reported to CMS, 2019-2025
30 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $1,161 · 2023: $403 · 2024: $829 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $369.11 | 2022-2025 | Evenity, Repatha |
| Alnylam Pharmaceuticals INC. | $357.52 | 2023-2025 | Amvuttra, Givlaari |
| Jazz Pharmaceuticals INC. | $243.95 | 2024-2025 | |
| Axsome Therapeutics, INC. | $240.68 | 2024-2025 | Auvelity |
| Alexion Pharmaceuticals, INC. | $203.88 | 2025 | Ultomiris |
| Scynexis, INC. | $186.31 | 2021-2022 | |
| Corcept Therapeutics | $179.82 | 2021-2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $160.39 | 2022 | |
| Novo Nordisk INC | $152.99 | 2021-2022 | |
| Sk Life Science, INC. | $151.69 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.64 | 2024-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $136.96 | 2024 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $134.59 | 2024 | Spravato |
| Boston Scientific Corporation | $134.29 | 2025 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $122.06 | 2025 | Uzedy |
| Astellas Pharma US INC | $122.06 | 2025 | Veozah |
| Catalyst Pharmaceuticals, INC. | $121.08 | 2022 | |
| Gilead Sciences, INC. | $112.38 | 2025 | Yeztugo |
| Edwards Lifesciences Corporation | $105.74 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.80 | 2025 | Rexulti |
| Shield Therapeutics INC | $93.01 | 2022 | |
| Amarin Pharma, INC. | $89.21 | 2025 | Vascepa |
| Glaxosmithkline, LLC. | $84.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $79.27 | 2023 | Farxiga |
| Abbvie INC. | $70.42 | 2022 | |
| Pfizer INC. | $67.59 | 2025 | |
| Molnlycke Health Care US, LLC | $50.75 | 2023 | Mepilex, Mepilex Border Post-Op, Mepilex Border Em |
| Medtronic, INC. | $31.44 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.